Double-Blind, Randomized, Controlled, Multi-Centered, Phase 2 Clinical Trial to Determine the Safety, Efficacy, and Immunogenicity of Booster Vaccination Against SARS-CoV-2
Latest Information Update: 16 Feb 2023
At a glance
- Drugs Eru-CoV-Vac (Primary) ; SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- 10 Feb 2023 Status changed from active, no longer recruiting to completed.
- 04 Apr 2022 Planned End Date changed from 11 Mar 2022 to 11 Sep 2022.
- 17 Nov 2021 Planned End Date changed from 12 Jul 2022 to 11 Mar 2022.